900 related articles for article (PubMed ID: 27851831)
1. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
[TBL] [Abstract][Full Text] [Related]
2. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency facilitates access to medicines in low- and middle-income countries.
Cavaller Bellaubi M; Harvey Allchurch M; Lagalice C; Saint-Raymond A
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):321-325. PubMed ID: 32053756
[No Abstract] [Full Text] [Related]
4. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
Dellepiane N; Akanmori BD; Gairola S; Jadhav SS; Parker C; Rodriguez C; Srivastava S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S428-33. PubMed ID: 26553671
[TBL] [Abstract][Full Text] [Related]
5. Global support for new vaccine implementation in middle-income countries.
Kaddar M; Schmitt S; Makinen M; Milstien J
Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496
[TBL] [Abstract][Full Text] [Related]
6. Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems.
Roth L; Bempong D; Babigumira JB; Banoo S; Cooke E; Jeffreys D; Kasonde L; Leufkens HGM; Lim JCW; Lumpkin M; Mahlangu G; Peeling RW; Rees H; Ndomondo-Sigonda M; Stergachis A; Ward M; Nwokike J
Global Health; 2018 Nov; 14(1):102. PubMed ID: 30382856
[TBL] [Abstract][Full Text] [Related]
7. Inequities in the global health workforce: the greatest impediment to health in sub-Saharan Africa.
Anyangwe SC; Mtonga C
Int J Environ Res Public Health; 2007 Jun; 4(2):93-100. PubMed ID: 17617671
[TBL] [Abstract][Full Text] [Related]
8. Industrial perceptions of medicines regulatory harmonization in the East African Community.
Dansie LS; Odoch WD; Årdal C
PLoS One; 2019; 14(6):e0218617. PubMed ID: 31216323
[TBL] [Abstract][Full Text] [Related]
9. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
[TBL] [Abstract][Full Text] [Related]
10. Social marketing and the fight against malaria in Africa: population services international (PSI) and insecticide treated nets (ITNS).
Omona J
East Afr J Public Health; 2009 Dec; 6(3):317-25. PubMed ID: 20803927
[TBL] [Abstract][Full Text] [Related]
11. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
So AD; Woo J
BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
[TBL] [Abstract][Full Text] [Related]
12. Conquering the intolerable burden of malaria: what's new, what's needed: a summary.
Breman JG; Alilio MS; Mills A
Am J Trop Med Hyg; 2004 Aug; 71(2 Suppl):1-15. PubMed ID: 15331814
[TBL] [Abstract][Full Text] [Related]
13. A quiet revolution in global public health: The World Health Organization's Prequalification of Medicines Programme.
't Hoen EF; Hogerzeil HV; Quick JD; Sillo HB
J Public Health Policy; 2014 May; 35(2):137-61. PubMed ID: 24430804
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs.
Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB
JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209
[TBL] [Abstract][Full Text] [Related]
15. The Manufacturers' Perspective on World Health Organization Prequalification of In Vitro Diagnostics.
Morin S; Bazarova N; Jacon P; Vella S
Clin Infect Dis; 2018 Jan; 66(2):301-305. PubMed ID: 29020182
[TBL] [Abstract][Full Text] [Related]
16. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.
Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM
Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723
[TBL] [Abstract][Full Text] [Related]
17. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
18. Access to essential medicines to treat chronic respiratory disease in low-income countries.
Bissell K; Perrin C; Beran D
Int J Tuberc Lung Dis; 2016 Jun; 20(6):717-28. PubMed ID: 27155173
[TBL] [Abstract][Full Text] [Related]
19. The art of partnerships for vaccines.
Pagliusi S; Che Y; Dong S
Vaccine; 2019 Sep; 37(40):5909-5919. PubMed ID: 31447125
[TBL] [Abstract][Full Text] [Related]
20. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
Pagliusi S; Dennehy M; Homma A
Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
